Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
When San Francisco-based Salesforce said in 2010 it was moving into Mission Bay, many in the life sciences community were disappointed that the medical and biotech enclave would be filled by high tech workers.
Bruce Spaulding, one of the architects of San Francisco’s Mission Bay biotech enclave, is retiring for health reasons from the foundation supporting the Gladstone Institutes.
A study led by a Johns Hopkins neuroscientist and published in the May 10 issue of the journal Neuronsuggests a potential new therapeutic approach for improving memory and interrupting disease progression in patients with a form of cognitive impairment that often leads to full-blown Alzheimer’s disease.
Rare is the soiree that makes science sizzle. But that was the fact last week during the Gladstone Institutes Gala at the Four Seasons Hotel, where 450 guests were greeted by lab-coat-wearing waiters bearing test tubes filled with cocktails.
History was made Thursday evening as an FDA panel recommended approval of a drug that could prevent the spread of HIV, the virus that causes AIDS -- a disease that has killed 30 million people around the world.
Gladstone Institutes' Senior Investigator Dr. Shinya Yamanaka is profiled for his pioneering work in stem cell technology.
SILVER SPRING, Md. — A drug already used to treat H.I.V.infection should also be approved to prevent it, an advisory panel to the Food and Drug Administration said on Thursday. The recommendation is the first time that government advisers have advocated giving antiviral medicine to healthy people who might be exposed through sexual activity to the virus that causes AIDS.
Research in mouse models of familial AD conducted at the Gladstone Institutes of San Francisco has identified mechanisms of the brain that contribute to abnormal excitatory brain activity, as reported in a paper published in the April 27 issue of the journal Cell.
For the first time in the 30-year battle against the HIV epidemic, a panel of experts has recommended that the Food and Drug Administration approve a drug to give to healthy people to protect against the infection.
A panel of US health experts has for the first time backed a drug to prevent HIV infection in healthy people.